Drugmaker stocks gained a temporary reprieve on Thursday as U.S. President Donald Trump spared pharmaceutical products from reciprocal tariffs, but executives and analysts warned it was premature to celebrate as tariffs were still likely to come.

After underperforming the overall market for the past few years, large-cap pharmaceutical stocks may now be positioned to outperform as the impact of tariffs on foreign products and services begins to take hold.

The Trump administration carved out an exception for pharmaceuticals from the president's new tariff regime, at least for now

The exemption may be short-lived if President Trump makes good on threats to use tariffs as leverage to bring drug production back to the United States.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, top-rated podcasts, and non-profit The Motley Fool Foundation.

The second executive at a drugmaker said his company was "stockpiling" in the United States, the pharma industry's biggest market worth about $630 billion, a step aimed at easing the immediate blow of tariffs if they are implemented. The sources spoke on ...

Pharmaceutical companies breathed a sigh of relief on Wednesday, but the tariff reprieve could prove fleeting.

Indian pharmaceutical stocks tumbled 4.4% on Friday, erasing gains from the previous session, after Trump threatened steep tariffs on the sector.

In recent years, the pharmaceutical landscape has witnessed a seismic shift as cannabinoids transition from niche alternatives to mainstream medical solutions.